Galderma shares new interim analysis data from trial for prurigo nodularis
Galderma has reported new interim analysis data from the OLYMPIA long-term extension trial of monoclonal antibody Nemluvio for the treatment …
Galderma has reported new interim analysis data from the OLYMPIA long-term extension trial of monoclonal antibody Nemluvio for the treatment …
Transgene has completed the initial subject screening for the Phase II segment of its Phase I/II trial of individualised neoantigen …
“Japan has the second biggest market for branded drugs and is the third largest market for pharmaceuticals overall,” says Kento …
At the 15th Annual Outsourcing in Clinical Trials (OCT) Europe conference, which took place between 29 and 30 April in …
Dizal has completed subject enrolment for the randomised Phase III WU-KONG28 trial of oral sunvozertinib for treating non-small cell lung …
AbbVie has announced that its Phase III TEMPLE study, which compared the oral calcitonin gene-related peptide (CGRP) receptor antagonist, atogepant, …
BioOrbit aims to kick off pre-clinical trials to study protein crystals for monoclonal antibodies (mAbs) produced in a pharmaceutical factory …
Biogen has commenced dosing in the Phase III BRAVE study to assess omaveloxolone in children of two to less than …
Autism spectrum disorder (ASD) is a neurodevelopmental disorder that includes a variety of differences or challenges with social communication and …
MSD and Daiichi Sankyo have announced first subject dosing in the randomised IDeate-Prostate01 Phase III trial of ifinatamab deruxtecan (I-DXd) …
With the 10-year Health Plan on the horizon, the NHS could learn some tricks from France, Germany and the Nordics. At …
Skyhawk Therapeutics has dosed the first subject in the randomised Phase II/III FALCON-HD trial of the oral small-molecule RNA splicing …
US Food and Drug Administration (FDA) Commissioner Dr. Marty Makary addressed concerns about the recent cuts impacting the agency’s ability …
Oncology clinical trials are complex and costly, making a successful setup critical. Facing challenges such as long timelines and patient …
Lyell Immunopharma has reported new clinical data from the Phase I/II clinical trial of autologous dual-targeting CD19/CD20 chimeric antigen receptor …